Solutions...

Pricing & Access
Strategies

Optimal pricing strategies for development decisions and market access.

Read more

Conjoint
Research

Delivering conjoint that can handle the intricacies of the pharma market.

Read more

Forecasting
Software

Allowing leading pharma companies to build evidence-based forecasts fast and easily.

Read more

Launch Sequence
Simulators

Get your country launch sequence right. Capture full value in the face of international reference pricing.

Read more

Training
Courses

Industry-leading pricing-for-market-access and forecasting training.

Read more

Pricing & Access Strategies

Pricing & market access research that expects the unexpected during drug development

Price based on what payers do, not just what they say

Rich consumers don’t take surveys. How to estimate willingness-to-pay?

Just asking payers what they would pay for “Product X” does not work

Develop win-win market access agreements with payers

Price based on what payers do, not just what they say

Behavior-Based Pricing™

Do you want more from your pricing research? Are you looking for pricing insights that are not based on misleading analogues or the statistically unreliable opinion of a handful of payers?

If so, Behavior-Based Pricing is an accurate, fast, and scalable alternative.

Behavior-Based Pricing gives you insight into how much payers value innovation.

Don’t just take our word for it: validations show Behavior-Based Pricing correctly predicts outcomes in 93% of payer decisions.

You can be confident you’ll know the right price to target in negotiations so that you don’t leave value on the table.

of top pharma already trust Inpharmation’s Behavior-Based Pricing.0%

Behavior-Based Pricing for:

  1. Early-development stage pharmaceutical value assessments
  2. Price change insights across indications, subpopulations, and scenarios
  3. Reliable insights, quickly and cost-effectively

Join leading pharma companies in knowing that your pricing strategies are founded on what payers will actually pay, not on what they say they will pay.

Image of city skyline by the beach

Rich consumers don’t take surveys. How to estimate willingness to pay?

Patient Willingness to Pay

Predicting patient willingness-to-pay with traditional research is costly, time-consuming, and biased – because rich people are not interested in the honoraria for taking patient surveys.

There is a smarter way.

Rich people are less likely to take surveys. However, and as you would expect, the richer they are, the more they are willing to pay for a given level of health gain. This means that we can predict patient willingness-to-pay by quantifying health gain (something we’ve been doing for decades) and feeding this into income distributions.

The result is a powerful and rapid technique that captures the willingness to pay of all patients – rich and poor.

This means you can gauge willingness-to-pay across the full range of incomes.

Make your revenue-optimizing strategies truly optimized.

Patient willingness-to-pay modeling excels when you want:

  1. Out-of-pocket strategies for emerging markets and lifestyle products.
  2. Patient price-elasticity.
  3. An efficient approach for multiple countries.

Optimize pricing. Maximize patient access. Drive success.

Just asking payers what they would pay for “Product X” does not work

Primary Research

Top pharma trust us as “gold-standard thought partners”  for pricing strategy when they want:

  • Price insights that are not based on the statistically unreliable views of a handful of payers.
  • To see how price impacts access and usage.
  • To identify the value drivers critical to pricing success and see exactly how much impact each one has.
  • To optimize their product’s positioning in the treatment landscape.
  • To be able to confidently understand, explain, and justify their strategy.

What’s more, our customers want dynamic results. They want to understand their best pricing strategy today and  tomorrow – if and when their clinical profile or competitive landscape has changed.

Simply asking payers what they would pay isn’t good enough for our clients. They want the full picture, and they want to keep that full picture as things evolve.

istockphoto-1455725431-1024×1024

Develop win-win market access agreements with payers

Innovative Contracting Simulator

When it comes to payer negotiations, failing to prepare is preparing to fail.

That’s where our innovative contracting simulator comes in. It has been designed to let you stay ahead in pricing negotiations by using forward-thinking strategies.

Our war-gaming engine leverages decades of pricing and modeling expertise, giving you the power to optimize payer agreements.

With it, you can:

  • Accurately model all major payer-contracting schemes.
  • Find the balance of what works for you and for payers.
  • Achieve win-win outcomes by simulating unlimited scenarios.

Top pharma use our innovative contracting simulator when they need:

  1. Sandbox environments to prepare for negotiations with payers.
  2. Standardized methods for contracting across countries.
  3. Flexible, error-free simulations.
Plan ahead. Master negotiations. Ensure patient access for your product.
This is a remarkable piece of work
Global Head
Biotech
Really great work and interesting insights for us. Thank you guys so much
Director
Top 10 Pharma
An exceptional tool!
Associate Director
Top 20 Pharma
Our accreditations
BHBIA logo, InnAward logo and EphMrA logo

We tailor our services to your exact requirements

Get in touch with us and arrange a meeting

Request a book sample chapter

Value Pricing for Market Access